{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:16:26Z","timestamp":1790878586440,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ccell.2024.10.016","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T10:36:02Z","timestamp":1732185362000},"page":"2098-2112.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade"],"prefix":"10.1016","volume":"42","author":[{"given":"Habib","family":"Hamidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Senbabaoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niha","family":"Beig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Koeppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe June","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barzin Y.","family":"Nabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobe","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Maund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Giltnane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Schedlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Edward E.","family":"Kadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Degaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Andreev-Drakhlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyasha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Mariathasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-6445","authenticated-orcid":false,"given":"Romain","family":"Banchereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2024.10.016_bib1","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.ccell.2024.10.016_bib2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd.2018.210","article-title":"Trial watch: The clinical trial landscape for PD1\/PDL1 immune checkpoint inhibitors","volume":"17","author":"Tang","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ccell.2024.10.016_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ccell.2024.10.016_bib4","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","article-title":"Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial","volume":"27","author":"Powles","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2024.10.016_bib5","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-21-3089","article-title":"Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials","volume":"28","author":"Bellmunt","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2024.10.016_bib6","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1038\/s41467-021-24112-w","article-title":"Molecular determinants of response to PD-L1 blockade across tumor types","volume":"12","author":"Banchereau","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2024.10.016_bib7","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ccell.2024.10.016_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2024.10.016_bib9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2024.10.016_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2024.10.016_bib11","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2024.10.016_bib12","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2024.10.016_bib13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2024.10.016_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2024.10.016_bib15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.eururo.2018.09.022","article-title":"The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer","volume":"75","author":"van Dijk","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ccell.2024.10.016_bib16","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2024.10.016_bib17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2024.10.016_bib18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ccell.2024.10.016_bib19","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2024.10.016_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular classification and diagnostics of upper urinary tract urothelial carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2024.10.016_bib21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","article-title":"The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability","volume":"75","author":"Kim","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ccell.2024.10.016_bib22","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2024.10.016_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2024.10.016_bib24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T\u00a0cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2024.10.016_bib25","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2024.10.016_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2024.10.016_bib27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2024.10.016_bib28","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2024.10.016_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2024.10.016_bib30","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1073\/pnas.0308531101","article-title":"Metagenes and molecular pattern discovery using matrix factorization","volume":"101","author":"Brunet","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2024.10.016_bib31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2024.10.016_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccell.2024.10.016_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/jama.2018.5602","article-title":"Big Data and Predictive Analytics: Recalibrating Expectations","volume":"320","author":"Shah","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ccell.2024.10.016_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","article-title":"Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer","volume":"40","author":"Patil","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2024.10.016_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020291","article-title":"Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer","volume":"9","author":"Mandelli","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ccell.2024.10.016_bib36","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","article-title":"Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2024.10.016_bib37","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1158\/1535-7163.MCT-22-0130","article-title":"Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfbeta-Dependent Mechanisms","volume":"21","author":"Yu","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2024.10.016_bib38","doi-asserted-by":"crossref","first-page":"TPS501","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS501","article-title":"A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced\/unresectable or metastatic urothelial cancer","volume":"39","author":"Grivas","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.10.016_bib39","article-title":"Mortality due to cancer treatment delay: systematic review and meta-analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ccell.2024.10.016_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41379-021-00919-2","article-title":"Digital pathology and artificial intelligence in translational medicine and clinical practice","volume":"35","author":"Baxi","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ccell.2024.10.016_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.10.016_bib42","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1200\/JCO.2023.41.6_suppl.518","article-title":"Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy","volume":"41","author":"Grivas","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.10.016_bib43","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2024.10.016_bib44","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12885-022-09478-4","article-title":"Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer","volume":"22","author":"Weickhardt","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ccell.2024.10.016_bib45","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2023.41.16_suppl.4504","article-title":"Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study","volume":"41","author":"Siefker-Radtke","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.10.016_bib46","article-title":"Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial","volume":"10","author":"Griffin","year":"2024","journal-title":"J.\u00a0Pathol. Clin. Res."},{"key":"10.1016\/j.ccell.2024.10.016_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cells10061510","article-title":"The PD-L1\/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer","volume":"10","author":"Yajuk","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ccell.2024.10.016_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd9436","article-title":"PD-L1(+) neutrophils contribute to injury-induced infection susceptibility","volume":"7","author":"Thanabalasuriar","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ccell.2024.10.016_bib49","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1038\/s41467-022-34722-7","article-title":"PD-L1 negatively regulates antifungal immunity by inhibiting neutrophil release from bone marrow","volume":"13","author":"Yu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2024.10.016_bib50","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1126\/science.adg8538","article-title":"Illusory generalizability of clinical prediction models","volume":"383","author":"Chekroud","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ccell.2024.10.016_bib51","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/s41467-021-21896-9","article-title":"Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes","volume":"12","author":"Diao","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2024.10.016_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.media.2022.102645","article-title":"RetCCL: Clustering-guided contrastive learning for whole-slide image retrieval","volume":"83","author":"Wang","year":"2023","journal-title":"Med. Image Anal."},{"key":"10.1016\/j.ccell.2024.10.016_bib53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41551-020-00682-w","article-title":"Data-efficient and weakly supervised computational pathology on whole-slide images","volume":"5","author":"Lu","year":"2021","journal-title":"Nat. Biomed. Eng."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610824004045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610824004045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T01:26:18Z","timestamp":1765243578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610824004045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1535610824004045"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2024.10.016","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2024.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}